Enhancement of Efficacy of Wilms’ Tumor Gene WT1 Product-derived Peptide Cancer Vaccine by Co-administration with Immunopotentiating Agents: Lessons from Mouse Models

摘要: To induce and activate tumor-associated antigen-specific cytotoxic T lymphocytes (CTLs) for cancer immunity, it is important not only to select potent CTL epitopes but also combine them with appropriate immunopotentiating agents. Wilms’ tumor gene W T1 expressed at high levels in many kinds of hematological solid malignancies. WT1 products have immunogenicity been reported serve as a promising antigen tumor-specific immunotherapy. We started peptide vaccine clinical trials since 2001, demonstrated that can WT1-specific immunologic responses the associated responses. enhance vaccine’s therapeutic efficacy, we investigated various agents co-administer vaccine, using mice models Mycobacterium bovis bacillus Calmette-Guerin cell wall skeleton (BCG-CWS), which well-known dendritic cells (DCs), i.e., innate could and/or CTLs combination vaccination. Interferon (IFN)-β type I IFN, known its anticancer properties. Co-administration IFN-β enhanced immunity mainly through induction CTLs, enhancement natural killer (NK) activity, promotion major histocompatibility complex (MHC) class expression on cells. vaccination combined BCG-CWS or thus be expected efficacy